CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need.
Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.
Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.
Employees: 11-50
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Innovation... | innovation... |
| - | BlueTree A... | bluetreeal... |
| - | Lehigh Val... | lehighvall... |
| - | AlphaLab H... | alphalabhe... |
Mentions in press and media 7
| Date | Title | Description |
| 26.09.2024 | CytoAgents: Cytokine Release Syndrome Treatment Company Receives Third Grant From NIH | CytoAgents – a clinical-stage biotechnology company dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS) – announced that it has been awarded a $2 million National Institutes of Health (NIH) grant, the ... |
| 14.06.2021 | Meet the 7 life science startups of AlphaLab Health’s inaugural accelerator cohort | Seven promising life science startups started off 2020 with a shot of support from two of the region’s health and economic development-minded orgs. Launched in September 2020, AlphaLab Health is an initiative of Innovation Works, which also... |
| 05.04.2021 | Seven early-stage health companies selected for Pittsburgh's inaugural AlphaLab Health accelerator cohort | Dr. Jeffrey Cohen, Chief Physician Executive for Community Health and Innovation at Allegheny Health Network (AHN) “This is a unique collaboration between two world-class organizations, and the first cohort marks a key milestone for our par... |
| 11.07.2020 | Broad Street Angels Hears Pitches from 3 Female CEO Entrepreneurs | Philadelphia, PA – Open for business and selecting high growth companies to pitch its members for investment, the Broad Street Angels held its July investment meeting with a lineup of 3 dynamic female CEO led companies. |
| 13.05.2020 | Pittsburgh has long been a life sciences engine. Now it’s at the forefront of COVID-19 vaccine efforts | If Dr. Louis Falo and his team at the University of Pittsburgh are successful, the same medical school that produced the vaccine that ended polio could produce the vaccine that ends COVID-19. “It’s great to be in this environment, with this... |
| - | CytoAgents Receives Second Round of NIH Funding to Accelerate Treatment for Cytokine Storm | PITTSBURGH--(BUSINESS WIRE)--Mar 10, 2021-- CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release ... |
| - | CytoAgents | - |